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1 Abstract 
 
Background: Among neuroendocrine tumours (NET) of the lung, typical (TC) and 
atypical (AC) carcinoids represent the low, small cell lung carcinomas (SCLC) and large cell 
neuroendocrine carcinomas (LCNEC) the high grade spectrum. The N-glycoprotein periostin 
(POSTN) was recently found to be upregulated in both tumour cell cytoplasm and 
peritumoural stroma of non-small cell lung carcinomas (NSCLC) in the context of epithelial-
mesenchymal transition (EMT). This study aimed at investigating periostin protein expression 
in NET in these respective compartments. 
Patients and Methods: Between 1993 and 2007, a retrospective multicenter cohort of 
192 patients with surgically resected NET or diagnosed as such at autopsy was investigated 
on a tissue microarray (TMA) by immunohistochemistry (IHC). Periostin immunoreactivity 
was semi-quantitatively scored in the cytoplasm of tumour epithelia and in the peritumoural 
stroma. Data was correlated with neuroendocrine (NE) categories, markers of neuroendocrine 
(synaptophysin, chromogranin A) or lung (TTF-1) differentiation, and the tumour 
proliferation rate Mib-1. 
Results: The cohort consisted of 58 TC, 42 AC, 32 LCNEC and 60 SCLC. 
Concerning neuroendocrine differentiation, chromogranin A was less tightly associated with it 
than synaptophysin. 
Cytosolic periostin expression was higher in carcinoids than in SCLC or LCNEC (p < 
0.001). There was no significant difference between POSTN expression in tumour cells and 
overall survival rate (p = 0.139). No (grade 0) or weak (grade 1-2) stromal staining with 
POSTN was detected in more than half of typical (70.7 %) and atypical carcinoids (54.8 %), 
whereas strong (grade 5-6) staining was observed in LCNEC (56.3 %) and SCLC (46.7 %). 
Thus high stromal expression of periostin was associated with higher tumour grade and the 
SCLC and LCNEC categories, respectively, as well as higher pTNM and therefore correlated 
with a decreased survival rate (p-values <0.05). Furthermore, besides proliferation, a 
correlation between high TTF-1 expression and worse prognosis was seen in high-grade NET. 
Conclusion: Aggressive clinical behaviour of SCLC and LCNEC corresponds not 
only with high proliferation rate and high expression of TTF-1 but also with the formation of 
a prominent desmoplastic stroma containing the EMT protein periostin. 
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2  Introduction 
 
Lung cancer is the most common cancer worldwide and, despite decline, the leading 
cause of cancer mortality in males. This is largely due to cigarette smoking. Over the past two 
generations, cancer mortality in females has also increased. It is estimated that approximately 
3000 deaths are caused by lung cancer every year in Switzerland.1 
Nearly all lung cancers are carcinomas and about 80 % of them belong to the non-
small cell group (NSCLC), whereas small cell lung cancer (SCLC) constitutes the majority of 
the rest.2 In early stages of the disease there are normally no symptoms. Therefore, the 
diagnosis in most cases will frequently be made too late, and the tumour has often 
metastasized at the time the patient enters the hospital. In 40-50 % of patients with NSCLC, at 
the time of diagnosis, the disease has already advanced to stages IIIb or IV.3 
Referring to an updated World Health Organization (WHO) classification of lung 
cancer published in 1999 4, neuroendocrine lung tumours (NET) are a distinct subset sharing 
certain morphological, ultrastructural, immunohistochemical, and molecular characteristics. 
The four major categories of morphologically identifiable NET are low-grade typical 
carcinoids (TC), intermediate-grade atypical carcinoids (AC), and the high-grade small cell 
lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC), respectively. TC 
is also called well-differentiated neuroendocrine tumour and AC well-differentiated 
neuroendocrine carcinoma. They all share neuroendocrine features of varying degrees, 
detectable by light microscopy.5 Neuroendocrine immunhistochemical markers are usually 
best performed as a panel consisting of synaptophysin, chromogranin, and CD56 / NCAM. To 
date, relatively little is known regarding the genetic changes associated with neuroendocrine 
lung tumours other than SCLC.6 
Histologically, typical carcinoids (TC) show a low mitotic rate (less than two per ten 
high-power fields) and lack of necrosis. Compared to TC, atypical carcinoids (AC) have a 
larger size with greater architectural disorganization and increased pleomorphism, more 
frequent mitoses (two to ten per ten high-power fields), tumour necrosis, a higher rate of 
metastases, and a significantly reduced survival rate. 
According to Travis et al.4-5,7-8, large cell neuroendocrine carcinoma (LCNEC) is a 
tumour composed of large cells characterised by a light microscopic neuroendocrine (NE) 
appearance such as organoid nesting, trabecular pattern, rosette formation, and basaloid 
palisading with a high nuclear to cytoplasmic ratio. A frequent presence of prominent 
macronucleoli, a high mitotic rate (more than 10 mitoses per 10 high power fields), and 
abundant necrosis is also seen. LCNEC is distinguished from the small cell type (SCLC) 
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primarily by the nuclear size: If nuclei are 3 times the diameter of a small resting lymphocyte, 
equal to > 30 micrometer, LCNEC is favoured. Further, a constellation of other criteria, which 
include larger cell size, abundant cytoplasm, prominent nucleoli, vesicular or coarse 
chromatin, polygonal shape, and less prominent nuclear moulding is also taken into account.  
On the other hand, tumour cells of SCLC have a small round or fusiform shape with 
salt and pepper chromatin and scant cytoplasm. They grow in sheets or nests with frequent 
necrosis and their nucleoli are inconspicuous or absent. Decisive for the correct classification 
of a large cell carcinoma as LCNEC is the detection of at least one immunohistochemical 
marker or an electron microscopic characterization.5,8 Several reports suggest that the 
prognosis of LCNEC is poor, with a variable overall 5-year survival rate ranging from 13% to 
45%.9-10 Another study confirmed that LCNEC shows almost the same prognosis as SCLC,11 
apart from displaying similar histopathologic patterns and common risk factors. Currently, 
patients with limited SCLC have a 5-year survival rate of 21 %.12 According to several recent 
studies, LCNEC responds to cisplatin-based chemotherapeutic regimens similar to those used 
for SCLC.13-15 Yet, optimum treatment for LCNEC remains undefined.16 In many centres a 
strategy of surgery followed by adjuvant chemotherapy is performed. 
Ki-67 (Kiel-67), a non-histone protein, is a DNA-binding nuclear protein expressed 
throughout the cell cycle in proliferating cells, but not in quiescent (G0) cells. It is detected by 
the antibody Mib-1 (mitotic labelling index). It has been used to distinguish growing from 
non-growing cells.17-19 In small crushed biopsies Ki-67 staining can be helpful to separate TC 
or AC from high-grade LCNEC or SCLC, which have very high proliferation rates.20-22  
Thyroid transcription factor-1 (TTF-1) is a nuclear protein playing an important role in 
the development and morphogenesis of thyroid, lung, and ventral forebrain.23 In normal adult 
tissues it is expressed in follicular cells of the thyroid, in Clara cells, type 2 pneumocytes of 
the lung, and in pituicytes.23-25 The lung epithelia surface is globally separated into a TTF-1 
positive peripheral (alveolar) and a TTF-1 negative central (bronchial) compartment. 
Therefore, the expression of TTF-1 in tumours deriving from the thyroid, lungs, and 
neurohypophysis is familiar.  
Epithelial-mesenchymal transition (EMT) is defined as transition of epithelial cells 
into cells with mesenchymal characteristics.26 During embryogenesis, epithelial cells may lose 
their epithelial characteristics by dissolving their cell contacts and down-regulating adhesion 
molecules such as E-cadherin. This permits cells to migrate and pass the basement membrane. 
Upon reaching their destination they can differentiate into different cells or re-differentiate 
into epithelial cells (mesenchymal-epithelial transition, MET). A prerequisite for the 
migration is a polarization of the cell. Moreover, the EMT is associated with cancer 
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progression and metastasis. Many studies in animals and cell culture experiments have 
demonstrated that carcinoma cells can acquire a mesenchymal phenotype and express 
mesenchymal markers (EMT proteins) such as α-SMA (alpha-smooth muscle actin), FSP1 
(fibroblast-specific protein 1), vimentin, and desmin.27 Particularly interesting among these 
EMT proteins is periostin (POSTN), a gene encoding a secreted 90 kDa protein showing 
sequence similarity to the insect adhesion molecule fasciclin I.28 This protein has been 
suggested to function as a cell adhesion molecule for preosteoblasts and to participate in 
osteoblast recruitment, attachment, and spreading.29-30 
The main goal of this work was to analyze the epithelial-mesenchymal transition 
protein periostin (POSTN) expression in different NE neoplasms and stromal tissue of the 
lung by tissue microarray (TMA) immunohistochemistry, using a polyclonal anti-POSTN 
antibody, and its correlation with established histopathological and prognostic factors. 
 
2.1 Objective target 
 
This work was carried out with the following objectives: 
1. Production of a tissue microarray with NET of the lung. 
2. Acquisition of pathological and clinical patient data. 
3. Immunohistochemical detection and analysis of expression of Ki-67, neuroendocrine 
markers (synaptophysin, chromogranin A), TTF-1 and POSTN. 
4. Statistical analysis of pathological parameters and of expression of the named markers. 
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3 Materials and methods 
 
3.1 Patients and tissue collection 
 
For the time period of 1993 to 2007 a total of 192 patients with surgically resected (n 
= 183) or autopsy diagnosed (n = 9) neuroendocrine tumours of the lung were investigated. 
Concerning SCLC, the data set is thus restricted to patients having limited, operable disease. 
They were retrieved from the computer databases of the University Hospital (n = 90) and the 
Triemli Hospital in Zurich (n = 29), as well as the Technical University of Munich (n = 73). 
The study was examined and accredited by the Institutional Ethical Review Board of the 
University Hospital of Zurich under reference number StV 29-2009. Because of insufficient 
material, 29 patients were excluded from the investigation. Additional information such as 
age, gender, and tumour size were gathered from pathology reports. Tumour stage, grade, and 
histological subtype were identified according to the TNM criteria, or as recommended by the 
UICC.31 Surgical and autopsy samples were processed by formalin-fixation and paraffin-
embedding according to the guidelines of the Swiss and the German Society of Pathology. 
Survival data from 164 patients was collected from the Cancer Registry Zurich (Dr. med. 
Dimitri Korol) and Munich (Prof. Dr. med. Aurel Perren). One hundred patients (52 %) were 
men and 92 (48 %) were women. The mean age was 57 years, ranging from 15 to 85 years. A 
tumour size with a mean diameter of 2.9 cm, ranging from 0.5 to 10 cm, was seen in 170 
patients. Table 1 shows an overview of the pathological and clinical parameters of the 
neuroendocrine lung tumours. In 19 patients, the tumour stage and nodal status could not be 
determined. Furthermore, survival data from 28 patients were missing. 
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Table 1. NET cohort of the lung. Pathological and clinical parameters. 
 
          Tissue Samples 
          n        % 
 
Total 192 100 
 
Histology SCLC 60 31.3 
 TC 58 30.2 
 AC 42 21.9 
 LCNEC 32 16.7 
 
Tumour stage pT1 104 60.1 
 pT2 55 31.8 
 pT3 7 4 
 pT4 7 4 
 
Nodal status pNx 19 9.9 
 pN0 126 65.6 
 pN1 25 13 
 pN2 20 10.4 
 pN3 2 1 
 
Metastases cM0 166 94.3 
 cM1 10 5.7 
 
Grading  G1 95 49.5 
 G2 5 2.6 
  G3 92 47.9 
 
Location 
 Side right 93 53.1 
  left 81 46.3 
  both 1 0.6 
 Bronchus main 8 9.3 
  upper lobe 36 41.9  
  middle lobe 15 17.4  
  lower lobe 20 23.3 
  > 1 7 8.1  
 Lobe upper lobe 77 45.8  
  middle lobe 23 13.7  
  lower lobe 54 32.1  
  > 1 14 8.3 
   
Survival alive 89 54.3 
 dead 75 45.7 
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3.2 Construction of Tissue Microarray  
 
According to a method established by Kononen et al.,32 a tissue microarray (TMA) 
was set up in order to enable a high-throughput molecular profiling of tumour specimens. The 
configuration of each tumour tissue and its coordinates were stored in a punch and picture file 
(see Figure 1). HE-stained slides of all tumours were reviewed and representative areas were 
selected. These were areas with characteristic histomorphology of the individual tumour. A 
total of 384 tumour tissue cylinders with a diameter of 0.6 mm were punched out from those 
areas of the corresponding paraffin blocks. From each tumour, two tissue cylinders were 
taken. Additionally, 16 punches of different control tissues, including normal tissue of the 
lung and palatine tonsil as well as neuroendocrine tumour tissue of the portio uteri, ileocoecal 
resectate, and appendix were collected. The complete set, comprising a total of 400 tissue 
cylinders, was precisely arrayed into a recipient paraffin block using a custom-made, semi-
automatic tissue microarray device (Beecher Instruments, Sun Prairie, WI, USA). The device 
and an overview of the TMA block are displayed in Figure 2. 
 
 
 
Figure 1. Picture file of TMA. 
 x x x x x x x x  x x x x x x x x  x x x x x x x x 
 1 2 3 4 5 6 7 8  1 2 3 4 5 6 7 8  1 2 3 4 5 6 7 8 
y      1 1 2 3 4 5 6 7 8  137 138 139 140 141 142 143 144  273 274 275 276 277 278 279 280 
y      2 9 10 11 12 13 14 15 16  145 146 147 148 149 150 151 152  281 282 283 284 285 286 287 288 
y      3 17 18 19 20 21 22 23 24  153 154 155 156 157 158 159 160  289 290 291 292 293 294 295 296 
y      4 25 26 27 28 29 30 31 32  161 162 163 164 165 166 167 168  297 298 299 300 301 302 303 304 
y      5 33 34 35 36 37 38 39 40  169 170 171 172 173 174 175 176  305 306 307 308 309 310 311 312 
y      6 41 42 43 44 45 46 47 48  177 178 179 180 181 182 183 184  313 314 315 316 317 318 319 320 
y      7 49 50 51 52 53 54 55 56  185 186 187 188 189 190 191 192  321 322 323 324 325 326 327 328 
y      8 57 58 59 60 61 62 63 64  193 194 195 196 197 198 199 200  329 330 331 332 333 334 335 336 
y      9 65 66 67 68 69 70 71 72  201 202 203 204 205 206 207 208  337 338 339 340 341 342 343 344 
y    10 73 74 75 76 77 78 79 80  209 210 211 212 213 214 x x  345 346 347 348 349 350 351 352 
y    11 81 82 83 84 85 86 87 88  217 218 219 220 221 222 223 224  353 354 355 356 357 358 359 360 
y    12 89 90 91 92 93 94 95 96  225 226 227 228 229 230 231 232  361 362 363 364 365 366 367 368 
y    13 97 98 99 100 101 102 103 104  233 234 235 236 237 238 239 240  369 370 371 372 373 374 375 376 
y    14 105 106 107 108 109 110 111 112  241 242 243 244 245 246 247 248  377 378 379 380 381 382 383 384 
y    15 113 114 115 116 117 118 119 120  249 250 251 252 253 254 255 256  385 386 387 388 389 390 391 392 
y    16 121 122 123 124 125 126 127 128  257 258 259 260 261 262 263 264  393 394 395 396 397 398 399 400 
y    17 129 130 131 132 133 134 135 136  265 266 267 268 269 270 271 272          
                           
  SCLC   TC    AC    LCNEC   normal   other x error 
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A 
 
 
B 
 
 
Figure 2. A: Tissue array device for the construction of the TMA. 
  B: Overview of the tissue microarray block. 
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3.3 Immunohistochemistry 
 
For immunohistochemical analysis, 4-µm-thick paraffin sections were cut from the 
TMA block and mounted on silane-coated glass slides. After incubation at 37°C overnight, 
deparaffinization in xylene, and rehydration through graded ethanol series, the sections were 
stained with a avidin-biotin-peroxidase complex method33 using  a Ventana automat (Ventana 
Medical Systems, Tucson, AZ) for Ki-67, synaptophysin (syn), chromogranin A (cg A), and 
TTF-1. For POSTN, we used a Bond automat (Vision Biosystems, Melbourne Australia) 
according to the following protocol: after boiling in Tris pH 8, containing buffer H2 for 30 
min, the slide was incubated with the rabbit polyclonal anti-POSTN antibody for 30 minutes 
at room temperature. Detection by means of secondary antibodies was performed with 
Ultraview Amp (Ventana) and Refine-DAB (Vision Biosystems) kits. The five antibodies, their 
dilutions, and the type of pretreatment are listed in Table 2. 
 
 
Table 2. Antibodies. 
 
Protein Antibody Clone Producer Dilution Pretreatment 
         Ki-67    Mouse Mib-1         DAKO         1:20     CC1m* 
         Syn    Mouse  27G12         Ventana   prediluted     CC1m* 
         Cg A    Mouse     LK2H10         Ventana   prediluted     CC1m* 
         TTF-1    Mouse      8G7G3/1         DAKO         1:50     CC1m* 
        POSTN    Rabbit        polyclonal  BioVendor         1:500     None 
 
*CC1 = Cell conditioning solution 1 (Ventana Medical Systems, Inc.): prediluted solution, which is used for the 
pretreatment for automatic immunostaining of tissue samples on the Ventana BenchMark device. 
m = mild cell condition (30 min boiling). 
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3.4 Interpretation of results 
 
For each core the intensity of immunoreactivity was semi-quantitatively scored on a 
four tiered scale, with grade 0 equivalent to no staining, grade 1 = weak, grade 2 = moderate, 
and grade 3 = strong. Epithelial and stromal protein expression of POSTN was scored by 
Andrej Atanassoff. Ki-67 was scored for frequency ranging from 0 to 100 % and intensity 
from 0 to 4 % equivalent to grade 0, 5-9 % = grade 1, 10-20 % = grade 2, and > 20 % = grade 
3 as well as syn, cg A, and TTF-1 for intensity only (0 to 3) by Andrej Atanassoff and 
Christian Oehlschlegel. The scores of both cores were summed up to range from 0 to 6 
resulting in grade 0, no staining, grade 1-2, weak, grade 3-4, moderate, and grade 5-6 
equivalent to strong staining. 
 
3.5 Statistical analysis 
 
Of the 221 original patients, 29 were excluded since no adequate tumour tissue was   
available. Of the 192 remaining patients, 28 were removed from the survival analysis due to 
lack of data. Survival calculations were thus computed on a total of 164 patients. The 
correlation between various pathological-anatomical or immunohistochemical parameters was 
investigated by multi-field for multiple groups or non-parametric Kruskal-Wallis test. For all 
investigations with respect to patient prognosis, the overall survival was chosen as the 
endpoint. For calculation of the survival time, living patients were evaluated as "censored".  
The illustration of the cumulative survival curves was performed by the method of 
Kaplan-Meier. A log rank test was used for the statistical assessment of differences between 
cumulative survival curves. Statistical analyses were performed using the statistical software 
package SPSS/PASW 16.0.0 (SPSS Inc., Chicago, IL, USA). P-values < 0.05 were considered 
statistically significant in all analyses. 
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4 Results 
 
4.1 Pathological-anatomical findings 
 
After completion of the TMA paraffin block, a 4-µm thin section was stained with 
Hematoxylin- Eosin (HE). All tumours were reviewed for morphology and compared with the 
data in the punch file. Figure 3 shows a digital photo of an HE-stained TMA section. 
Examples of histomorphological types of NET of the lung are illustrated in Figures 4-7. 
 
 
 
 
Figure 3. HE-stained TMA section. Original size: 2 x 1.3 cm. 
 
 
A a 
 
 
Figure 4. A: SCLC, magnification: 10x; a: magnification: 40x. 
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B b 
 
 
Figure 5. B: TC, magnification: 10x; b: magnification: 40x. 
 
 
C c 
ddff 
 
Figure 6. C: AC, magnification: 10x; c: magnification: 40x. 
 
 
D d 
 
 
Figure 7. D: LCNEC, magnification: 10x; d: magnification: 40x. 
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The tumour stage, nodal status, the presence of metastases, and grading were closely 
associated with the patients` prognosis (p < 0.001). Significant differences were also found 
with the individual types of NET of the lung (p < 0.001). The correlations between these 
parameters and overall survival regardless of the tumour type are shown in Figures 8-11. 
Figure 12 illustrates overall survival considering well versus poorly differentiated 
neuroendocrine lung tumours. Table 3 indicates the 5-year survival rate of the four tumour 
types. 
 
 
 
Figure 8. Tumour stage and overall survival. 
 
 
 
   Figure 9. Nodal status and overall survival. 
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   Figure 10. Metastases and overall survival. 
 
 
 
   Figure 11. Grading and overall survival. 
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   Figure 12. Well versus poorly differentiated NET of the lung and overall survival. 
 
 
Table 3. Overall 5-year survival according to tumour type.  
 
    
 
 
 
 
    
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Type 
Overall 5-year 
survival  
 SCLC     21.0 % 
      TC     97.2 % 
      AC         93.5 % 
   LCNEC         24.0 % 
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4.2 Immunohistochemical findings 
 
In order to determine the correlation between protein expression and pathological 
parameters, the data obtained from the analysis with the antibodies Ki-67, synaptophysin, 
chromogranin A, TTF-1 and periostin was compared with the histological type of tumour. On 
the basis of survival data, it was possible to calculate the clinical significance of individual 
molecular parameters. The tumour stage, nodal status, the presence of metastases, and grading 
were also included in the calculations. 
 
4.2.1 Ki-67 
 
Any Ki-67 positivity was observed in 102 of 192 analyzable NET of the lung (53.1 
%).  A Ki-67 negative AC and a strong Ki-67 positive SCLC is shown in Figure 13. It is 
known that SCLC and LCNEC have a higher proliferation rate than TC and AC. This is also 
seen in Table 4. There was a significant positive correlation between strong Ki-67 positivity 
and high grade NET, higher tumour stage pT3 / pT4, higher nodal stage pN2 / pN3, presence 
of metastases, and higher grading G3. 
 
 
A B 
 
 
 
Figure 13. A: Ki-67 negative AC. Magnification: 10x. 
    B: Strong Ki-67 positive SCLC. Magnification: 10x. 
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Table 4. Ki-67 expression and histopathological parameters. 
 
                  Ki-67 sum intensity scores 
                0                   1                   2                   3                   4                   5                 6 
          n            n (%)            n (%)            n (%)            n (%)            n (%)            n (%)          n (%) 
Histology SCLC      60          4 (6.7)                                1 (1.7)          1 (1.7)          4 (6.7)         6 (10.0)    44 (73.3) 
p < 0.001  TC      58      54 (93.1)          3 (5.2)                                                     1 (1.7) 
  AC      42      31 (73.8)          4 (9.5)           2 (4.8)                             5 (11.9) 
  LCNEC      32          1 (3.1)                                1 (3.1)                               2 (6.3)         4 (12.5)    24 
(75.0) 
 
Tumour stage pT1 / pT2   159      85 (53.5)          7 (4.4)           3 (1.9)          1 (0.6)          8 (5.0)           8 (5.0)    47 (29.6) 
p < 0.001  pT3 / pT4     14          1 (7.1)                                                                       2 (14.3)                          11 (78.6) 
 
Nodal Status pN0 / pN1  151      82 (54.3)          7 (4.6)           2 (1.3)          1 (0.7)          5 (3.3)           8 (5.3)    46 (30.5) 
p < 0.003                 pN2 / pN3    22        4 (18.2)                                1 (4.5)                            5 (22.7)                          12 (54.5) 
 
Metastasis cM0            166      86 (51.8)          7 (4.2)           3 (1.8)                              9 (5.4)           8 (4.8)    53 (31.9) 
p < 0.001  cM1              10                                                                       1 (10.0)       1 (10.0)                            8 (80.0) 
 
Grading  G1 / G2      100      85 (85.0)          7 (7.0)           2 (2.0)                              6 (6.0) 
p < 0.001  G3                92          5 (5.4)                                2 (2.1)          1 (1.1)         6 (6.5)       10 (10.9)    68 (73.9) 
 
 
The result of the prognostic significance of Ki-67 mitotic labelling index in NET of 
the lung is shown in Figure 14. A negative (grade 0) or low (grade 1-2) Ki-67 expression had 
no clinical significance. But a strong (grade 5-6) Ki-67 positivity was significantly associated 
with worse prognosis (p < 0.001).  
 
 
 
Figure 14. Ki-67 mitotic labelling index and overall survival in lung NET.  
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4.2.2 Synaptophysin (syn) 
 
Any expression of synaptophysin was detected in a total of 184 of 192 analyzable 
NET of the lung (95.8 %). Figure 15 illustrates a syn negative LCNEC and a strong syn 
positive TC. The correlation between syn expression and tumour type is shown in Table 5. 
There was a significant positive correlation between strong syn positivity and carcinoids, 
lower tumour stage pT1 / pT2, and lower grading G1 / G2.  
 
 
A B 
 
 
 
Figure 15. A: Syn negative LCNEC. Magnification: 10x. 
    B: Strong syn positive TC. Magnification: 10x.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
Table 5. Syn expression and histopathological parameters. 
 
                            Syn sum intensity scores 
                0                  1                    2                    3                  4                   5                6 
          n            n (%)           n (%)             n (%)             n (%)           n (%)            n (%)          n (%) 
Histology SCLC      60          4 (6.7)        7 (11.7)       13 (21.7)         8 (13.3)          5 (8.3)          2 (3.3)    21 (35.0) 
p < 0.001  TC      58          1 (1.7)                                2 (3.4)           2 (3.4)          2 (3.4)          4 (6.9)    47 (81.0) 
  AC      42                                                     2 (4.8)                               1 (2.4)                         39 (92.9) 
  LCNEC      32          3 (9.4)                              6 (18.8)         5 (15.6)        8 (25.0)          3 (9.4)      7 (21.9) 
 
Tumour stage pT1 / pT2   159          6 (3.8)          5 (3.1)         13 (8.2)         13 (8.2)        13 (8.2)          7 (4.4)  102 (64.2) 
p = 0.008  pT3 / pT4     14          1 (7.1)                              5 (35.7)           1 (7.1)        2 (14.3)          1 (7.1)      4 (28.6) 
 
Nodal Status pN0 / pN1  151          7 (4.6)          5 (3.3)         14 (9.3)         13 (8.6)        12 (7.9)          8 (5.3)    92 (60.9) 
p = 0.785                pN2 / pN3    22                                                   4 (18.2)           1 (4.5)        3 (13.6)                        14 (63.6) 
 
Metastasis cM0            166          7 (4.2)          4 (2.4)       17 (10.2)         13 (7.8)        15 (9.0)          8 (4.8)  102 (61.4) 
p = 0.413  cM1              10                             1 (10.0)         2 (20.0)         1 (10.0)                             1 (10.0)     5 (50.0) 
 
Grading  G1 / G2      100           1 (1.0)                               4 (4.0)           2 (2.0)          3 (3.0)          4 (4.0)    86 (86.0) 
p < 0.001  G3                92           7 (7.6)          7 (7.6)       19 (20.7)       13 (14.1)      13 (14.1)         5 (5.4)    28 (30.4) 
 
 
A negative, weak or moderate (grade 3-4) syn expression was significantly associated 
with poor prognosis (p < 0.001). The result of this statistical analysis is shown in Figure 16. 
 
 
 
   Figure 16. Syn expression and overall survival in lung NET. 
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4.2.3 Chromogranin A (cg A) 
 
Any chromogranin A expression was observed in 148 of 192 analyzable NET of the 
lung (77.1%). Figure 17 illustrates examples of a cg A negative SCLC and a strong cg A 
positive TC. The correlation between the expression of cg A and the tumour type is shown in 
Table 6. There was a significant positive correlation between strong cg A positivity and 
carcinoids, lower tumour stage pT1 / pT2, lower nodal stage pN0 / pN1, absence of 
metastases, and lower grading G1 / G2. 
 
 
A B 
  
 
Figure 17. A: Cg A negative SCLC. Magnification: 10x. 
    B: Strong cg A positive TC. Magnification: 10x. 
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Table 6. Cg A expression and histopathological parameters. 
 
                           Cg A sum intensity scores 
                0                  1                    2                    3                  4                   5                6 
          n            n (%)           n (%)             n (%)             n (%)           n (%)            n (%)          n (%) 
Histology SCLC      60      30 (50.0)          4 (6.7)       19 (31.7)           2 (3.3)          5 (8.3) 
p < 0.001  TC      58          1 (1.7)          1 (1.7)           1 (1.7)           2 (3.4)      11 (19.0)          4 (6.9)    38 (65.5) 
  AC      42          1 (2.4)                                2 (4.8)           2 (4.8)      13 (31.0)          1 (2.4)    23 (54.8) 
  LCNEC      32      12 (37.5)        5 (15.6)       10 (31.3)           3 (9.4)          1 (3.1)                             1 (3.1) 
 
Tumour stage pT1 / pT2   159      32 (20.1)          9 (5.7)       17 (10.7)           8 (5.0)      27 (17.0)          5 (3.1)    61 (38.4) 
p = 0.002  pT3 / pT4     14        6 (42.9)                              7 (50.0)                                                                       1 (7.1) 
 
Nodal Status pN0 / pN1  151      31 (20.5)          7 (4.6)       18 (11.9)           8 (5.3)      24 (15.9)          5 (3.3)    58 (38.4) 
p = 0.022                pN2 / pN3    22        7 (31.8)          2 (9.1)         6 (27.2)                              3 (13.6)                           4 (18.2) 
 
Metastasis cM0            166      36 (21.7)          9 (5.4)       20 (12.0)          8 (4.8)       26 (15.7)          5 (3.0)    62 (37.3) 
p = 0.043  cM1              10        2 (20.0)        1 (10.0)         5 (50.0)                              2 (20.0) 
 
Grading  G1 / G2      100          2 (2.0)          1 (1.0)           3 (3.0)           4 (4.0)       24 (24.0)          5 (5.0)   61 (61.0) 
p < 0.001  G3                92      42 (45.7)          9 (9.8)       29 (31.5)           5 (5.4)           6 (6.5)                            1 (1.1) 
 
 
A negative or weak cg A expression was significantly associated with poor prognosis 
(p < 0.001). The result of this statistical analysis is shown in Figure 18. 
 
 
 
 
Figure 18. Cg A expression and overall survival in lung NET.  
 
 
 
 24 
4.2.4 Thyroid transcription factor-1 (TTF-1) 
 
Any TTF-1 expression was detected in a total of 124 of 192 analyzable NET of the 
lung (64.6 %). Figure 19 illustrates a TTF-1 negative AC and a strong TTF-1 positive 
LCNEC. The relations between TTF-1 and histopathologic parameters are listed in Table 7. 
There was a significant positive correlation between strong TTF-1 positivity and high grade 
NET, presence of metastases, and higher grading G3. 
 
 
A B 
 
Figure 19. A: TTF-1 negative AC. Magnification: 10x. 
    B: Strong TTF-1 positive LCNEC. Magnification: 10x. 
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Table 7. TTF-1 expression and histopathologic parameters. 
 
                          TTF-1 sum intensity scores 
                0                  1                    2                    3                  4                   5                6 
          n            n (%)           n (%)             n (%)             n (%)           n (%)            n (%)          n (%) 
Histology SCLC      60      12 (20.0)          3 (5.0)       13 (21.7)           5 (8.3)        9 (15.0)          2 (3.3)    16 (26.7) 
p < 0.001  TC      58      32 (55.2)          3 (5.2)       18 (31.0)           2 (3.4)          3 (5.2) 
  AC      42      22 (52.4)          4 (9.5)       13 (31.0)           1 (2.4)          2 (4.8) 
  LCNEC      32          2 (6.3)        5 (15.6)         8 (25.0)           3 (9.4)        4 (12.5)          1 (3.1)      9 (28.1) 
 
Tumour stage pT1 / pT2   159      59 (37.1)        13 (8.2)       45 (28.3)           9 (5.7)        14 (8.8)          1 (0.6)    18 (11.3) 
p = 0.192  pT3 / pT4     14        4 (28.6)          1 (7.1)         2 (14.3)         2 (14.3)          1 (7.1)          1 (7.1)      3 (21.4) 
 
Nodal Status pN0 / pN1  151      58 (38.4)        10 (6.6)       40 (26.5)         11 (7.3)        13 (8.6)          1 (0.7)    18 (11.9) 
p = 0.445                pN2 / pN3    22        5 (22.7)        4 (18.2)         7 (31.8)                                2 (9.1)          1 (4.5)      3 (13.6) 
 
Metastasis cM0            166      63 (38.0)        14 (8.4)       43 (25.9)          9 (5.4)         15 (9.0)          2 (1.2)    20 (12.0) 
p = 0.006  cM1              10                                                  4 (40.0)         2 (20.0)         1 (10.0)                          3 (30.0) 
 
Grading  G1 / G2      100      54 (54.0)          7 (7.0)       31 (31.0)           3 (3.0)           5 (5.0) 
p < 0.001  G3                92      14 (15.2)          8 (8.7)       21 (22.8)           8 (8.7)       13 (14.1)         3 (3.3)    25 (27.2) 
 
 
The result of the prognostic significance of TTF-1 expression in NET of the lung is 
shown in Figure 20. A strong (grade 5-6) TTF-1 expression was significantly associated with 
worse prognosis (p = 0.003).  
 
 
 
   Figure 20. TTF-1 expression and overall survival in lung NET. 
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4.2.5 Periostin (POSTN) 
 
Any POSTN protein expression in the cytoplasm of tumour epithelia was observed in 
183 of 192 analyzable NET of the lung (95.3 %), whereas stromal staining occurred in 165 
tumours (85.9 %). A SCLC with POSTN negative cytoplasm and an AC with strong POSTN 
positive cytoplasm are illustrated in Figure 21a. Figure 21b indicates a TC with POSTN 
negative peritumoural stroma and a LCNEC with strong POSTN positive peritumoural 
stroma. The relations between POSTN upregulation in the tumour cell respectively in the 
peritumoural stroma and the histopathologic parameters are listed in Table 8a and 8b (see also 
Figure 22). POSTN immunoreactivity in the cytoplasm of carcinoids and LCNEC was higher 
than in the cytoplasm of SCLC (p < 0.001). It was also correlated with lower stage (as a trend, 
p = 0.054), absence of metastases (p = 0.047) and lower grade (p < 0.001). Inversely, 
peritumoural periostin expression was higher in SCLC and LCNEC than in carcinoids (p < 
0.001). Further, high stromal POSTN was correlated with higher stage pT (p = 0.048), 
presence of lymph node (p = 0.05, as trend) and organ metastases (p = 0.006). 
 
 
A B 
 
Figure 21a. A: SCLC with POSTN negative cytoplasm. Magnification: 10x. 
      B: AC with strong POSTN positive cytoplasm. Magnification: 10x. 
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A B 
 
Figure 21b. A: TC with POSTN negative peritumoural stroma. Magnification: 10x. 
      B: LCNEC with strong POSTN positive peritumoural stroma. Magnification: 10x. 
 
 
Table 8a. Tumour epithelial expression of POSTN and histopathological parameters. 
 
               POSTN sum intensity scores in tumours 
                0                  1                    2                    3                  4                   5                6 
          n            n (%)           n (%)             n (%)             n (%)           n (%)            n (%)          n (%) 
Histology SCLC      60        6 (10.0)        6 (10.0)       16 (26.7)       11 (18.3)      12 (20.0)          2 (3.3)      7 (11.7) 
p < 0.001  TC      58          2 (3.4)          2 (3.4)           2 (3.4)         7 (12.1)      17 (29.3)          5 (8.6)    23 (39.7) 
  AC      42          1 (2.4)                                1 (2.4)         5 (11.9)      12 (28.6)          3 (7.1)    20 (47.6) 
  LCNEC      32                               1 (3.1)           3 (9.4)           3 (9.4)        9 (28.1)      11 (34.4)      5 (15.6) 
 
Tumour stage pT1 / pT2   159          6 (3.8)          5 (3.1)       18 (11.3)       18 (11.3)      44 (27.7)      20 (12.6)    48 (30.2) 
p = 0.054  pT3 / pT4     14                             3 (21.4)           1 (7.1)         4 (28.6)        3 (21.4)         1 (7.1)       2 (14.3) 
 
Nodal Status pN0 / pN1  151          3 (2.0)          7 (4.6)       16 (10.6)       21 (13.9)       41 (27.2)     18 (11.9)    45 (29.8) 
p = 0.302                pN2 / pN3    22        3 (13.6)          1 (4.5)         3 (13.6)           1 (4.5)         6 (27.3)       3 (13.6)      5 (22.7) 
 
Metastasis cM0            166          6 (3.6)         8 (4.8)         16 (9.6)       20 (12.0)       46 (27.7)     21 (12.7)     49 (29.5) 
p = 0.047  cM1              10            1(10)                             4 (40.0)         2 (20.0)         1 (10.0)                          2 (20.0) 
 
Grading  G1 / G2      100          3 (3.0)          2 (2.0)          3 (3.0)        12 (12.0)       29 (29.0)        8 (8.0)     43 (43.0) 
p < 0.001  G3                92          6 (6.5)          7 (7.6)      19 (20.7)        14 (15.2)       21 (22.8)    13 (14.1)     12 (13.0)  
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Table 8b. POSTN expression in peritumoural stroma and histopathological parameters. 
 
       POSTN sum intensity scores in peritumoural stroma 
                0                  1                    2                    3                  4                   5                6 
          n            n (%)           n (%)             n (%)             n (%)           n (%)            n (%)          n (%) 
Histology SCLC      60          1 (1.7)          3 (5.0)         8 (13.3)       10 (16.7)      10 (16.7)      15 (25.0)    13 (21.7) 
p < 0.001  TC      58      18 (31.0)        6 (10.3)       17 (29.3)         7 (12.1)          4 (6.9)          5 (8.6)        1 (1.7) 
  AC      42        7 (16.7)        7 (16.7)         9 (21.4)         9 (21.4)        5 (11.9)          3 (7.1)        2 (4.8) 
  LCNEC      32          1 (3.1)                                2 (6.3)         4 (12.5)        7 (21.9)      10 (31.3)      8 (25.0) 
 
Tumour stage pT1 / pT2   159      26 (16.4)        15 (9.4)       32 (20.1)       25 (15.7)      20 (12.6)      24 (15.1)    17 (10.7) 
p = 0.048  pT3 / pT4     14                              1 (7.1)          2 (14.3)         2 (14.3)        3 (21.4)        4 (28.6)      2 (14.3) 
 
Nodal Status pN0 / pN1  151      23 (15.2)        15 (9.9)       33 (21.9)       22 (14.6)      22 (14.6)      21 (13.9)      15 (9.9) 
p = 0.05                pN2 / pN3    22          3 (13.6)          1 (4.5)           1 (4.5)         5 (22.7)          1 (4.5)        7 (31.8)      4 (18.2) 
 
Metastasis cM0            166     26 (15.7)        16 (9.6)        34 (20.5)       26 (15.7)      22 (13.3)      24 (14.5)    18 (10.8) 
p = 0.006  cM1              10                                                  1 (10.0)         1 (10.0)        1 (10.0)        5 (50.0)      2 (20.0) 
 
Grading  G1 / G2      100      25 (25.0)      13 (13.0)       26 (26.0)       16 (16.0)          9 (9.0)          8 (8.0)        3 (3.0) 
p < 0.001  G3                92          2 (2.2)          3 (3.3)       10 (10.9)       14 (15.2)      17 (18.5)      25 (27.2)    21 (22.8) 
 
 
 
Figure 22. POSTN sum intensity scores in the NET cytoplasm and the surrounding 
desmoplastic stroma. 
 
 
As shown in Figure 23a, there was no relevant difference between POSTN expression 
in epithelial tumour cells and overall survival (p = 0.139). But a strong POSTN positivity in 
the peritumoural stroma was closely associated with worse prognosis, as seen in Figure 23b (p 
= 0.003). 
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Figure 23a. Epithelial expression of POSTN and overall survival in lung NET. 
 
 
 
Figure 23b. POSTN expression in peritumoural stroma and overall survival in lung 
NET. 
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5 Discussion 
 
Tissue microarrays (TMA) allow efficient analysis of molecular markers in malignant 
human tumours. Using 0.6 mm punch cores, > 600 different tumours may be scored 
simultaneously within a short a period of time without damaging or depleting too much tissue. 
Moreover, the costs for fluid agents used for analysis such as fluorescence in situ 
hybridization (FISH), RNA in situ hybridization (ISH) or immunohistochemistry (IHC) are 
significantly reduced. For one TMA section the same reaction volume is administered as 
needed for a single large section. TMAs also allow full anonymity of the tissue samples with 
preservation of the collected clinical information and simplify the research cooperation 
between various institutions. Although it must be kept in mind that a potential limitation of 
TMA is that small core samples might not be representative of an entire tumour, particularly 
so in heterogeneous cancers,34 the use of TMA has the advantage of enabling protein 
profiling, which probably more closely reflects the biologic characteristics of the tumour cells 
than does RNA detection. 
Besides histomorphological criteria, neuroendocrine (NE) markers (synaptophysin 
(syn), chromogranin A (cg A)) were helpful to classify all tumours. Rarely, both tumour TMA 
cores, especially considering cases of  SCLC or LCNEC, showed no staining for both syn 
(SCLC 6.7 %, LCNEC 9.4 %) and cg A (SCLC 50 %, LCNEC 37.5 %). These tumours were 
nevertheless included in the study, since in the archival reports NE differentiation was 
verified via positivity for syn or cg A or via an additional marker such as CD56 or NSE. Cg A 
is generally assumed to be less significant than syn concerning NE differentiation.35 This was 
also observable in the present cohort. Rossi et al.36 found the following percentage of 
immunohistochemical expression in LCNEC for cg A (65%) and syn (53%). Hiroshima et 
al.37 detected the following percentage of immunohistochemical staining with syn and cg A in 
SCLC (syn 57 %, cg A 36 %) and LCNEC (syn 77 %, cg A 59 %).  
Molecular mechanisms associated with neuroendocrine tumours (NET) of the lung and 
cancer progression in general remain poorly understood. During the past decade, global gene 
expression profiling studies on various human cancer types, mainly relying on cDNA 
microarray technology, led to the identification of new candidate genes involved in cancer 
progression. In this study, special interest was given to the epithelial-mesenchymal transition 
(EMT) protein periostin (POSTN). Up-regulation of this protein was observed in various 
cancers such as breast38, colon39, head and neck40 and oral41 cancer. Previous work in non-
small cell lung carcinoma (NSCLC) by Sasaki et al.42 showed that POSTN immunoreactivity 
in serum could be determined using sandwich ELISA (enzyme linked immunosorbent assay). 
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Furthermore, POSTN mRNA was detected at the border of epithelial tumour cells and 
surrounding stroma.43 Recently, Soltermann et al.44 studied the prognostic relevance of this 
EMT indicator protein POSTN in NSCLC. POSTN was found to correlate with squamous cell 
histotype, higher pT, larger size and higher grade. Further, it was a prognosticator for 
decreased progression-free survival on univariate analysis (p-value 0.007). In general, POSTN 
protein seems to play an important role in invasion, angiogenesis, and metastasis, as 
demonstrated by using tumour cell lines and mice models. However, another study45 has 
shown that the expression of POSTN is significantly downregulated in human bladder cancer 
tissues and that POSTN suppresses cell invasiveness and metastasis of cancer cells, thus 
rather acting as a tumour suppressor. 
The major objective of this work was to comprehensively investigate both epithelial 
and stromal periostin (POSTN) expression in all 4 categories of NET of the lung and its 
correlation with histopathological parameters. Epithelial and stromal staining with any 
distinct POSTN intensity (grade 1-6) was seen in all four neuroendocrine (NE) categories. 
Epithelial POSTN expression with strong staining was found as follows: small cell lung 
carcinoma (SCLC) 15.0 %, typical carcinoid (TC) 48.3 %, atypical carcinoid (AC) 54.8 %, 
large cell neuroendocrine carcinoma (LCNEC) 50.0 %. POSTN immunoreactivity in the 
cytoplasm of TC/AC and LCNEC was higher than in the cytoplasm of SCLC. However, this 
could be primarily due to the fact that SCLCs have very scant cytoplasm. No relation with 
overall survival was observed. The functional significance of cytosolic POSTN expression in 
tumour epithelia still remains unclear. It does not seem to be an effect of passive influx, since 
mRNA is detectable by ISH.38,42-43 Rather, tumour cells at the invasion front up-regulated 
expression of EMT proteins themselves in order to facilitate movement into their own newly 
formed desmoplastic stroma. No or weak stromal staining with POSTN was detected in over 
half of typical (70.7 %) and atypical carcinoids (54.8 %), whereas strong staining was 
observed with frequencies of 56.3 % in LCNEC and 46.7 % in SCLC. In other words, strong 
POSTN positivity in the peritumoural stroma correlates with high-grade NET of the lung (p < 
0.001). Both tumour entities thus have a highly active desmoplastic stroma. As expected and 
seen in Fig. 22, LCNEC has somewhat more stromal POSTN expression than SCLC. Large 
cell carcinomas generally have more prominent desmoplastic stroma than SCLCs, which 
present more “lymphoid tissue-like” with extensive necrosis. Some authors reported POSTN 
upregulation in about half of the NSCLC tumours46 and a slight increase in POSTN serum 
levels from NSCLC patients.42 Higher POSTN serum levels were also associated with higher 
T- or N-stage in SCLC patients;43 but other authors found a down-regulation of POSTN gene 
transcription in SCLC tumours by in situ mRNA hybridization.47 Furthermore, peritumoural 
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up-regulation of POSTN in SCLC and LCNEC is prognostically significant concerning 
overall survival (p = 0.003). In addition to its prognostic significance.  
A strong expression of the proliferation marker Ki-67 is associated with tumour stage, 
nodal status or grading in various types of tumours. Regardless of classic pathological 
parameters, presence of Ki-67 is also prognostically relevant in tumours such as bladder48-49 
or prostate cancer,50 and is therefore routinely used in cancer diagnosis. Often, the Ki-67 
labeling index (Mib-1) was adducted for the evaluation of Ki-67. It indicates the percentage of 
tumour cells expressing Ki-67 in a specific tumour site. An elevated Mib-1 is often associated 
with late tumour stage or high-grade of differentiation. However, it is difficult to find an 
optimal threshold, which allows statements about the prognosis. Depending on the analyzed 
tumour type, but also according to staining intensity and evaluation of each pathologist, the 
thresholds of Mib-1 vary considerably. To work around this problem, the scores of both cores 
of each tumour were added up to a sum of 0 to 6, which simplified the statistical calculations 
in this study. 
Based on the present results and early studies 7,13,51 LCNEC have a higher proliferation 
activity than TC and AC. Thus, Ki-67 helps to distinguish low-grade from high-grade NE 
lung tumours. Furthermore, Ki-67 expression in SCLC and LCNEC correlates with 
pathological parameters such as tumour stage, nodal status, presence of metastasis or grading. 
A strong Ki-67 positivity in high-grade NET is significantly associated with poor survival (p 
< 0.0001). 
In lung tumours, thyroid transcription factor-1 (TTF-1) is mainly expressed in 
adenocarcinoma and high-grade NET (SCLC and LCNEC), but it is absent in squamous cell 
carcinoma (SCC).52-55 The frequency of TTF-1 expression in SCLC (80 %), but not in 
LCNEC (93.7 %), found in this study are similar to the results published by Folpe et al.56 and 
Sturm et al.57 But there were also found frequencies of TTF-1 in 57 % of SCLC and 24 % of 
LCNEC.37 A possible explanation for the high expression of TTF-1 in LCNEC in this study is 
that different antibody clones and IHC protocols are used. Immunoreactivity of TTF-1 is 
known to be clone-dependent. Further, these tumours could be combined with other 
histological tumour types such as SCLC or adenocarcinomas. A strong TTF-1 positivity was 
observed in high-grade NET, which was significantly associated with poor prognosis (p = 
0.003). As far as concerning SCLC, this was as well seen by Hiroshima et al.37 This cohort 
study reported that 44.8 % of TC and 47.6 % of AC were TTF-1 positive. Some authors 
suggested a high specificity and sensitivity for TTF-1 immunohistochemistry following 
detection of pulmonary carcinoids58 while others did not find any TTF-1 expression in typical 
and atypical carcinoids.29,37-38,57,59-60 This discrepancy could be related to differences in 
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immunohistochemical techniques or in assessing the threshold of positivity. However, TTF-1 
could be a helpful marker in differentiating pulmonary from gastrointestinal carcinoids.61-62 
In general, the study shows that the possible heterogeneity within a tumour does not 
substantially affect the results of TMA analysis. Although the small tissue samples of TMA in 
individual cases are not always representative of the entire tumour, this error factor due to the 
large number of well-selected tumours and tumour areas is balanced, so that relevant clinical-
pathological correlations remain detectable.32,63-66 
The growing number of TMA-literature data shows that the TMA technology has 
become an indispensable tool in cancer research. It is expected that the use of TMA in 
particular to evaluate the clinical relevance of molecular changes is much easier. Furthermore, 
collected tumour collectives in large standardized prospective studies could be transferred to a 
TMA format, from which new opportunities would arise for cooperation, validation of 
research results and the achievement of an international consensus. For example, a new 
promising prognostic factor in all existing analog collectives could be verified within a short 
period of time. Such a decision was recently taken for e.g. the EML4-ALK translocation in 
NSCLC by ETOP (European Thoracic Oncology Platform). In order to obtain consistent 
FISH data, all TMAs must have the same design, consisting of 4 cores of 1 mm diameter each 
per tumour.  
In conclusion, this immunohistochemical investigation describes the differential 
expression in both tumour epithelial and peritumoural stroma of the EMT protein periostin in 
the 4 major categories of lung NET and its correlation to histopathological and prognostic 
factors. Aggressive clinical behaviour of SCLC and LCNEC corresponds not only with high 
mitotic proliferation rate but also with the formation of a prominent desmoplastic stroma with 
high metabolic activity. 
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